Ditchcarbon
  • Contact
  1. Organizations
  2. Mylan S.p.A.
Public Profile
Research Pending

This profile hasn't yet passed our validation checks

Submit your email to push it up the queue

We'll prioritize this organization's research and notify you when detailed sustainability data becomes available.

Pharmaceutical Preparation Manufacturing
IT
updated a month ago

Mylan S.p.A.

Company website

Mylan S.p.A., a prominent player in the global pharmaceutical industry, is headquartered in Italy and operates extensively across Europe, North America, and other key regions. Founded in 1961, Mylan has established itself as a leader in generic and specialty medications, focusing on improving access to high-quality healthcare solutions. The company offers a diverse portfolio of products, including generic drugs, over-the-counter medications, and complex generics, which are distinguished by their affordability and efficacy. Mylan's commitment to innovation and quality has earned it a strong market position, with notable achievements in expanding access to essential medicines worldwide. With a focus on patient-centric solutions, Mylan continues to play a vital role in the healthcare landscape, striving to meet the evolving needs of patients and healthcare providers alike.

DitchCarbon Score

How does Mylan S.p.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

45

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Mylan S.p.A.'s score of 45 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.

68%

Let us know if this data was useful to you

Mylan S.p.A.'s reported carbon emissions

Inherited from Viatris Inc.

Mylan S.p.A., headquartered in Italy, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Viatris Inc., which means that any climate commitments or emissions data may be inherited from its parent organisation. As of now, Mylan S.p.A. has not outlined specific reduction targets or initiatives in its own documentation. However, it is important to note that Viatris Inc. has established various climate commitments, which may influence Mylan's sustainability strategies. These commitments include participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded to Mylan S.p.A. from Viatris Inc. at a corporate family level. While Mylan S.p.A. has not disclosed its own emissions or reduction targets, the overarching goals set by Viatris Inc. may guide its climate action efforts in the future. The absence of specific data highlights the need for further transparency and commitment to climate action within the pharmaceutical sector.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2015201620172018201920202021202220232024
Scope 1
302,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 2
354,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
-
-
-
-
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Mylan S.p.A.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Mylan S.p.A. is in IT, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Mylan S.p.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

STADA Arzneimittel Aktiengesellschaft

DE
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Diocle S.p.A.

IT
•
Real estate services (70)
Updated 24 days ago

Teva Pharmaceutical Fine Chemicals S.r.l

IT
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251007.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy